Changes of GH-IGFs and its relationship with growth retardation in children with bronchial asthma

Abstract

Objective

To explore the relationship between Growth Hormone Insulin-like Growth Factors (GH-IGFs) and growth retardation in children with bronchial asthma.

Methods

112 children with bronchial asthma and 50 healthy children were studied. Serum GH, IGF-1, and Insulin-like Growth Factor Binding Protein 3 (IGFBP3) were assessed by ELISA. GH-IGFs-related parameters were compared, and the correlation between the parameters and bronchial asthma severity was analyzed. The bronchial asthma group was divided into the growth retardation group and non-growth retardation group to analyze the diagnostic value of GH-IGFs in growth retardation and the relationship between GH-IGFs and growth retardation.

Results

GH, IGF-1, and IGFBP3 in the bronchial asthma group were lower. GH, IGF-1, and IGFBP3 levels were decreased with the severity of bronchial asthma. GH, IGF-1, and IGFBP3 in the growth retardation group were lower than those in the non-growth retardation group. The AUC of GH-IGFs combined detection was higher than that of GH and IGFBP3 alone detection. GH < 9.27 μg/L and IGF-1 < 179.53 mmoL/L were risk factors for growth retardation in patients with bronchial asthma.

Conclusion

GH-IGFs-related parameters have diagnostic value for growth retardation in children, and decreased levels of GH and IGF-1 are risk factors for growth retardation in children.

Keywords
Children Bronchial Asthma; Growth Hormone; Insulin-like Growth Factor Ⅰ; Insulin-like Growth Factor Binding Protein 3; Growth Retardation

Highlights

• GH-IGFs-related parameters.

• GH-IGFs-related parameters in patients with different severity of bronchial asthma.

• Correlation analysis of GH-IGFs-related parameters and severity of bronchial asthma.

• GH-IGFs-related parameters in patients with or without growth retardation.

• Diagnostic value of GH-IGFs-related indicators in growth retardation.

• Logistic regression analysis of GH-IGFs-related indicators and growth retardation.

Highlights

• GH-IGFs-related parameters.

• GH-IGFs-related parameters in patients with different severity of bronchial asthma.

• Correlation analysis of GH-IGFs-related parameters and severity of bronchial asthma.

• GH-IGFs-related parameters in patients with or without growth retardation.

• Diagnostic value of GH-IGFs-related indicators in growth retardation.

• Logistic regression analysis of GH-IGFs-related indicators and growth retardation.

Introduction

Pediatric bronchial asthma is a heterogeneous disease characterized by chronic airway inflammation. At the onset of the disease, sporadic or diffuse wheezing rale in the expiratory phase can be heard in both lungs, and patients are often accompanied by variable expiratory airflow limitation, recurrent wheezing, shortness of breath, chest tightness, or cough. Bronchial asthma is a chronic inflammation involving a variety of inflammatory cells, which can cause airway damage, and then lead to airway smooth muscle thickening.¹ Insulin-like Growth Factor-1 (IGF-1) is involved in the repair process of airway epithelium and alveolar injury.² It has been reported in the past that the growth of airway epithelial cells can be promoted by regulating IGF-1 concentration.³ IGFs are a class of insulin-like peptides that promote cell differentiation and proliferation and are the main factors in the Growth Hormone (GH) - Insulin-like Growth Factors (GH-IGFs). There is a feedback regulatory system between IGF-1 and GH. GH can promote the synthesis and release of IGF-1, while IGF-1 can increase the hypothalamic somatostatin secretion and inhibit the release of GH or directly inhibit the synthesis of GH by pituitary GH cells, thereby reducing GH levels.⁴ GH-IGFs is related to the growth of children.⁵ Bone growth and development are mainly regulated by IGF-1′s endocrine function. GH can act on target cells to directly promote cell differentiation and proliferation and stimulate the production of IGF-1 in peripheral tissues.⁶ However, there is no clear report on its relationship with the growth of children with bronchial asthma. Therefore, the purpose of this study was to explore the relationship between GH-IGFs and growth retardation in children with bronchial asthma to provide a reference for the assessment of the disease and the growth of children.

Data and methods

Clinical data

112 children with bronchial asthma (bronchial asthma group) and 50 healthy children (control group) from January 2021 to January 2022 were studied, showing no significant difference in clinical data between the two groups (p > 0.05, Table 1).

Table 1
General data between the bronchial asthma group and the control group.

Items	Bronchial asthma group(n = 112)	Control group(n = 50)	χ2/t	p
Gender
Male	62	31	0.131	0.716
Female	50	19
Age (years)	8.92 ± 1.17	8.76 ± 1.21	0.672	0.503
Course of disease (days)	10.52 ± 2.03	10.98 ± 2.15	1.1	0.274
Maternal height (cm)	161.29 ± 4.67	162.02 ± 4.73	0.777	0.439
Paternal height (cm)	172.85 ± 5.06	172.79 ± 5.11	0.059	0.953
Family history of asthma	13	5	0.09	0.764

Inclusion criteria

① Meeting the diagnostic criteria for bronchial asthma;⁷;

② Age < 14 years old;

③ Complete clinical data.

Exclusion criteria

① Severe cardiac, liver and renal dysfunction;

② Congenital diseases;

③ Intrauterine growth retardation;

④ Other lung diseases;

⑤ Abnormal thyroid function;

⑥ Intracranial tumor disease.

Bronchial severity

The bronchial asthma group was divided into grades 1, 2, 3 and 4 according to the Guideline for the diagnosis and optimal management of asthma in children.

GH-IGFs-related parameter detection

Centrifuge treatment was conducted on the KDC-1042 high-speed centrifuge (Anhui Zhongke Zhongjia Scientific Instrument Co., Ltd.) at 3000 r/min for 10-min, with the centrifuge radius of 15 cm. Serum was separated to measure GH, IGF-1, and Insulin-like Growth Factor Binding Protein-3 (IGFBP3) on a Lab systems Dragou Wellscan K-3 microplate reader using enzyme-linked immunosorbent assay.

Diagnostic criteria for growth retardation

The physical standard of children with developmental delay is 30 % lower than that of children in the same state.⁸

Outcome measures

1. GH-IGFs-related parameters were compared, and the correlation between each parameter and the severity of bronchial asthma was analyzed.

2. The bronchial asthma group was divided into the growth retardation group and non-growth retardation group according to the growth conditions, and the diagnostic value of GH-IGFs related indicators for growth retardation and its relationship with growth retardation were analyzed.

Statistical analysis

Statistics were processed using SPSS22.0 software. Enumeration data (%) were compared by χ² test. Measurement data ($\overline{x}$ ± s) after the normality test were compared by t-test or multivariate analysis of variance. Spearman test was conducted to analyze the correlation between GH-IGFs and the severity of bronchial asthma. ROC curve was plotted to analyze the diagnostic value of GH-IGFs in growth retardation. Logistic regression was applied to analyze the relationship between GH-IGFs and growth retardation; p < 0.05 meant that the difference was statistically significant.

Results

GH-IGFs-related parameters

GH, IGF-1, and IGFBP3 levels in the bronchial asthma group were lower than those in the control group (p < 0.05, Fig. 1).

Fig. 1
GH-IGFs-related parameters in bronchial asthma.

GH-IGFs-related parameters in patients with different severity of bronchial asthma

GH, IGF-1, and IGFBP3 in patients with bronchial asthma showed a decreasing trend with the severity of the disease (p < 0.05, Fig. 2).

Fig. 2
GH-IGFs-related parameters in patients with different severity of bronchial asthma.

Correlation analysis of GH-IGFs-related parameters and severity of bronchial asthma

A negative correlation was found between GH, IGF-1, and IGFBP3 levels and asthma severity (p < 0.05, Fig. 3).

Fig. 3
Correlation analysis between GH-IGFs-related parameters and severity of bronchial asthma.

GH-IGFs-related parameters in patients with or without growth retardation

GH, IGF-1, and IGFBP3 in the growth retardation group were lower than those in the non-growth retardation group (p < 0.05, Fig. 4).

Fig. 4
GH-IGFs-related parameters in patients with or without growth retardation.

Diagnostic value of GH-IGFs-related indicators in growth retardation

The AUC of the combined detection of GH-IGFs-related indicators in the diagnosis of growth retardation was greater than that of GH and IGFBP3 alone (p < 0.05, Table 2 and Fig. 5).

Table 2
Diagnostic value analysis of GH-IGFs system related indexes in growth retardation.

Parameters	Cut-off value	AUC	SE	95 %CI
GH	9.27 μg/L	0.811a	0.049	0.715ཞ0.907
IGF-1	179.53 mmoL/L	0.905	0.028	0.850ཞ0.960
IGFBP3	8.12 mmoL/L	0.677a	0.06	0.559ཞ0.795
Combined		0.941	0.021	0.899∼0.982

Compared with combined.
• ^a
  p < 0.05.

Fig. 5
ROC curve analysis of GH-IGFs-related indicators in diagnosis of growth retardation in children with bronchial asthma. Note: Comparison between the two groups (*p < 0.05).

Logistic regression analysis of GH-IGFs-related indicators and growth retardation

GH <9.27 μg/L and IGF-1 < 179.53 mmoL/L were risk factors for growth retardation in patients with bronchial asthma (p < 0.05, Table 3).

Table 3
Logistic regression analysis of GH-IGFs-related indicators and growth retardation.

Parameters	β	SE	waldχ2	OR	95 %CI	p
GH	−0.614	0.197	9.714	0.541	0.368ཞ0.796	0.002
IGF-1	−0.118	0.028	17.76	0.889	0.841ཞ0.939	<0.001
IGFBP3	−0.228	0.227	1.009	0.796	0.510ཞ1.242	0.316
Constant	2.35	0.513	20.985	10.486	3.836ཞ28.659	<0.001

Assignment: GH (≥ 9.27 μg/L is 1, < 9.27 μg/L is 0); IGF-1 (≥ 179.53 mmol/L is 1, < 179.53 mmoL/L is 0); IGFBP3 (≥ 8.12 mmoL/L is 1, < 8.12 mmoL/L is 0).

Discussion

Children's bronchial asthma is a respiratory disease that seriously affects children's physical and mental health. As this chronic inflammatory response persists, the airway is in a state of hyper-responsiveness, and the symptoms will occur repeatedly upon stimuli exposure.⁹ Inflammatory cells are involved in bronchial asthma and cause airway injury and airway smooth muscle thickening.¹⁰ IGF-1 is involved in the repair process of airway epithelium and alveolar injury,¹¹ and regulating IGF-1 concentration can promote the growth of airway epithelial cells, suggesting that IGF-1 is involved in the process of airway epithelial cell proliferation.¹² Blood IGF-1 can participate in the negative feedback regulation of GH by inhibiting GH expression and transcription in the pituitary gland and stimulating GH release in the hypothalamus. GH can directly act on osteoblasts to promote cell proliferation and increase type I collagen synthesis. IGF-1 can stimulate the repair of osteoblast progenitor cells, and osteoblast differentiation, and induce bone collagen synthesis. IGFBP3 is a polypeptide containing multiple amino acids, which is less responsive to GH than IGF-1. Exogenous GH can increase IGF-1 and IGFBP3 in blood, and IGF-1 infusion can decrease GH concentration, suggesting that the amount of GH in blood is closely related to that of IGF-1.¹³¹⁴ In this study, GH, IGF-1, and IGFBP3 in the bronchial asthma group were lower than those in the control group, indicating the abnormal expression of GH-IGFs in children with bronchial asthma, which may be related to the involvement of IGF-1 in the repair of airway epithelium and alveolar injury. In addition, GH, IGF-1, and IGFBP3 were negatively correlated with the severity of bronchial asthma, suggesting that the severity of the disease could be assessed by detecting GH-IGFs-related parameters.

Children's is jointly regulated by the GH-IGFs. GH is secreted by adenohypophysis and regulated by growth hormone releasing hormone. Its growth-promoting effect is mainly mediated by IGF-1 and IGF-2, and IGFs secretion depends on GH. Under normal circumstances, IGF-1 level is mainly regulated by GH, and serum IGF-1 level can reflect the synthesis and release of GH. In blood circulation, IGFBP3 can combine with IGF-1 to form a complex, prolong the half-life of IGF-1 in blood vessels, and increase IGF-1 levels in blood. IGFBP3 can be degraded by IGFBP3 protease, and after degradation, the affinity between IGFBP3 and IGF-1 decreases, thereby releasing more free IGF-1 and enhancing the growth-promoting function of IGF-1.¹⁵¹⁶

In children, GH-IGFs regulate Children's and metabolism, and the growth-promoting effect of GH is mainly mediated by IGF-1 secreted by the liver.¹⁷¹⁸ GH binding to GHR in target cells triggers IGFs expression and secretion, wherein IGF-1 enters the tissues by binding to IGFBP, and the growth-promoting and anabolic effects of IGF-1 are triggered by IGF-I binding to IGF-IR in target organs.¹⁹²⁰ In this study, GH, IGF-1, and IGFBP3 in the growth retardation group were lower than those in the non-growth retardation group. The AUC of the combined detection of GH-IGFs-related indicators in the diagnosis of growth retardation was greater than that of GH and IGFBP3 alone. In addition, GH < 9.27 μg/L and IGF-1 < 179.53 mmoL/L were risk factors for growth retardation in children with bronchial asthma, indicating that decreased GH and IGF-1 could lead to growth retardation in children. The reason is that GH can stimulate peripheral tissues, especially the liver, to secrete IGF-1, which can promote organ development and activate bone anabolism. The effect of GH on growth is mediated by IGF-1, so abnormal IGF-1 can also affect Children.²¹-²³

In summary, abnormal GH-IGFs-related indicators exist in children with bronchial asthma, and GH-IGFs-related indicators in children are of diagnostic value for growth and development, and decreased levels of GH and IGF-1 are risk factors for growth retardation in children.

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author upon reasonable request.

Ethics approval

The present study was approved by the Ethics Committee of Ganzhou People's Hospital and written informed consent was provided by all patients prior to the study start. All procedures were performed in accordance with the ethical standards of the Institutional Review Board and The Declaration of Helsinki, and its later amendments or comparable ethical standards.

Acknowledgements

Not applicable.

• Funding
  Jiangxi Provincial Health and Family Planning Commission Science and Technology Program (SKJP220203187).

References

• ¹
  Xie X, Xu D, Zhuang L, Liu H, Tan S, Lu Y, et al. Sanfu herbal patch applied at acupoints in patients with bronchial asthma: study protocol for a randomized controlled trial. Trials. 2020;21(1):684-9.
• ²
  Liu Y, Nelson MV, Bailey C, Zhang P, Zheng P, Dome JS, et al. Correction: Targeting the HIF-1α-IGFBP2 axis therapeutically reduces IGF1-AKT signaling and blocks the growth and metastasis of relapsed anaplastic Wilms tumor. Oncogene. 2022;41(9):1383-1405.
• ³
  Bagheri-Hosseinabadi Z, Rezazadeh Zarandi E, Mirabzadeh M, Amiri A, Abbasifard M. mRNA expression of toll-like receptors 3, 7, 8, and 9 in the nasopharyngeal epithelial cells of coronavirus disease 2019 patients. BMC Infect Dis. 2022;22(1):448-53.
• ⁴
  Salama RH, Rasheed Z, Ahmed AA, Bin Saif GA, Elkholy MM, El-Moniem AEA, et al. Missense, silent, non-sense and frame-shift mutations in exon 3 of the filaggrin gene in patients with bronchial asthma, atopic dermatitis, allergic rhinitis and mixed atopy. Nucleosides Nucleotides Nucleic Acids. 2021;40(3):357-67.
• ⁵
  Andersson CK, Iwasaki J, Cook J, Robinson P, Nagakumar P, Mogren S, et al. Impaired airway epithelial cell wound้ealing capacity is associated with airway remodelling following RSV infection in severe preschool wheeze. Allergy. 2020;75(12):3195-207.
• ⁶
  Yeap BB, Hui J, Knuiman MW, Paul CSA, Ken K Y H, Flicker L, et al. Associations of plasma IGF1, IGFBP3 and estradiol with leucocyte telomere length, a marker of biological age, in men. Eur J Endocrinol. 2020;182(1):23-33.
• ⁷
  Kurniawan F, Tahapary DL, de Ruiter K, Yunir E, Biermasz NR, Smit JWA, et al. Effect of anthelmintic treatment on serum free IGF-1 and IGFBP-3: a cluster-randomized-controlled trial in Indonesia. Sci Rep. 2020;10(1):e19023.
• ⁸
  Ferrari U, Schmidmaier R, Jung T, Reincke M, Martini S, Schoser B, et al. IGF-I/IGFBP3/ALS deficiency in sarcopenia: low GHBP suggests GH resistance in a subgroup of geriatric patients. J Clin Endocrinol Metab. 2021;106(4):e1698-e1707.
• ⁹
  Rajhans P, Sagar R, Patra BN, Bhargava R, Kabra SK. Psychiatric morbidity and behavioral problems in children and adolescents with bronchial asthma. Indian J Pediatr. 2021;88(10):968-73.
• ¹⁰
  Mikalsen IB, Halvorsen T, Juliusson PB, Magnus M, Nystad W, Stensrud T, et al. Early life growth and associations with lung function and bronchial hyperresponsiveness at 11-years of age. Respir Med. 2021;177(1):e106305.
• ¹¹
  Umar MM, Ramachandran P, Vinoth PN. G507(P) Zinc status in children with bronchial asthma. Arch Dis Child Educ Pract Ed. 2019;104(2):A204-A209.
• ¹²
  Klevebro S, Hellgren G, Hansen-Pupp I, Wackernagel D, Hallberg B, Borg J, et al. Elevated levels of IL-6 and IGFBP-1 predict low serum IGF-1 levels during continuous infusion of rhIGF-1/rhIGFBP-3 in extremely preterm infants. Growth Horm IGF Res. 2020;50:1-8.
• ¹³
  Grenov B, Larnkjær A, Lee R, Serena A, Mølgaard C, Michaelsen KF, et al. Circulating insulin-like growth factor-1 is positively associated with growth and cognition in 6- to 9-year-old schoolchildren from Ghana. J Nutr. 2020;150(6):1405-12.
• ¹⁴
  Alkan F, Ersoy B, Kizilay DO, Coskun S. Cardiac functions in children with growth hormone deficiency: Effects of one year of GH replacement therapy. Growth Horm IGF Res. 2021;12(2):60-1.
• ¹⁵
  Ng EFY, Kaida A, Nojima H, Miura M. Roles of IGFBP-3 in cell migration and growth in an endophytic tongue squamous cell carcinoma cell line. Sci Rep. 2022;12(1):e11503.
• ¹⁶
  Wang L-J, Huang Y-H, Chou W-J, Lee S-Y. Growth hormone and thyroid function in children with attention deficit hyperactivity disorder undergoing drug therapy. J Clin Endocrinol Metab. 2022;107(7):2047-56.
• ¹⁷
  Hörenz C, Vogel M, Wirkner K, Ceglarek U, Thiery J, Pfäffle R, et al. BMI and contraceptives affect new age-, sex-, and puberty-adjusted IGF-I and IGFBP-3 reference ranges across life span. J Clin Endocrinol Metab. 2022;107(7):e2991-e3002.
• ¹⁸
  Babiker A, Al Noaim K, Al Swaid A, Alfadhel M, Deeb A, Martín-Rivada A, et al. Short stature with low insulin-like growth factor 1 availability due to pregnancy-associated plasma protein A2 deficiency in a Saudi family. Clin Genet. 2021;100(5):601-6.
• ¹⁹
  Kim S-Y, Kim M, Oh Y, Lee D-Y. Relationship of serum total insulin-like growth factor binding protein-3 with insulin-like growth factor-i and glucose tolerance in Korean children and adolescents. Int J Endocrinol. 2021;22(6):e9966114.
• ²⁰
  Tsai CW, Chang WS, Xu Y, Huang M, Bau D-T, Gu J. Associations of genetically predicted circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 with bladder cancer risk. Mol Carcinog. 2021;60(11):726-33.
• ²¹
  Gaddas M, Périn L, Le Bouc Y. Evaluation of IGF1/IGFBP3 molar ratio as an effective tool for assessing the safety of growth hormone therapy in small-for-gestational-age, growth hormone-deficient and prader-willi children. J Clin Res Pediatr Endocrinol. 2019;1(3):253-61.
• ²²
  Zhao Q, Zhang M, Ji B, Chu Y, Pan H, Yan W, et al. Relationship between hemoglobin and insulin-like growth factor-1 in children and adolescents with idiopathic short stature. BMC Endocr Disord. 2020;20(1):119-25.
• ²³
  Fujimoto M, Khoury JC, Khoury PR, Kalra B, Kumar A, Sluss P, et al. Anthropometric and biochemical correlates of PAPP-A2, free IGF-I, and IGFBP-3 in childhood. Eur J Endocrinol. 2020;182(3):363-74.

Publication Dates

• Publication in this collection
  24 June 2024
• Date of issue
  2024

History

• Received
  7 Nov 2023
• Accepted
  26 Apr 2024